The effect of anti-migraine compounds on nitric oxide-induced dilation of dural meningeal vessels

Eur J Pharmacol. 2002 Oct 4;452(2):223-8. doi: 10.1016/s0014-2999(02)02307-5.


Migraine is characteristically accompanied by a throbbing quality of head pain thought to involve trigeminovascular afferents. Administration of nitric oxide (NO) donors provides the most reliable model of migraine induction in humans. The present studies used intravital microscopy to monitor the effect of local meningeal nerve stimulation and NO on dural blood vessels and any modulation of that effect by anti-migraine compounds. NO caused an immediate and reproducible dilation of meningeal blood vessels that was partially blocked by sumatriptan and indomethacin, while flunarizine and histamine H(1) and H(2) receptor antagonists were unable to block the dilation. Indomethacin also inhibited the neurogenic dilation while flunarizine did not. The present studies demonstrate that NO is unlikely to interact with histamine to produce its dilatory response. Sumatriptan and indomethacin inhibit the NO response by inhibiting trigeminal activation and calcitonin gene-related peptide (CGRP) release. Flunarizine does not modify either the neurogenic vasodilator response or the NO meningeal dilator response at least acutely.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics / pharmacology*
  • Analgesics / therapeutic use
  • Animals
  • Dura Mater / blood supply
  • Dura Mater / drug effects*
  • Dura Mater / metabolism
  • Male
  • Meningeal Arteries / drug effects*
  • Meningeal Arteries / metabolism
  • Migraine Disorders / drug therapy
  • Migraine Disorders / metabolism*
  • Nitric Oxide / biosynthesis*
  • Nitric Oxide Donors / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Vasodilation / drug effects*
  • Vasodilation / physiology


  • Analgesics
  • Nitric Oxide Donors
  • Nitric Oxide